BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 17135642)

  • 1. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
    Leung SF; Zee B; Ma BB; Hui EP; Mo F; Lai M; Chan KC; Chan LY; Kwan WH; Lo YM; Chan AT
    J Clin Oncol; 2006 Dec; 24(34):5414-8. PubMed ID: 17135642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
    N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
    Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
    Tan EL; Looi LM; Sam CK
    Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma.
    Mutirangura A; Pornthanakasem W; Theamboonlers A; Sriuranpong V; Lertsanguansinchi P; Yenrudi S; Voravud N; Supiyaphun P; Poovorawan Y
    Clin Cancer Res; 1998 Mar; 4(3):665-9. PubMed ID: 9533535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
    Zhang Y; Gao HY; Feng HX; Deng L; Huang MY; Hu B; Cheng G; Wu QL; Cui NJ; Shao JY
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):982-6. PubMed ID: 15312530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.
    Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
    Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
    Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
    Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
    Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.